Hematology

The recommended addition is based on a uniform consensus that the therapy is an appropriate treatment for this difficult-to-treat disease.

Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.

In-person visits to receive oral therapy, outpatient infusions, and inpatient infusion for the treatment of hematologic neoplasms declined in the early months of the COVID-19 pandemic, while telemedicine use increased slightly in the same period but remained low overall.

Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.

A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Study highlights the importance of interprofessional decision-making between pharmacists and emergency department medical officers.

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.

Multiple myeloma treatment selection is critical due to the potential for developing treatment resistance over time to the currently prescribed drugs.

Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.

Lili Wang, MD, PhD, discusses her research investigating how METTL3 regulates RNA splicing dysregulation and contributes to CLL growth.

The treatment showed significant improvement in patients in patients who require frequent blood transfusions and are at risk of infection.

The APPOINT-PNH study showed that twice-daily LNP023 (Iptacopan) helped patients with paroxysmal nocturnal hemoglobinuria control intravascular hemolysis.

Less than 20% of physicians were open to starting a patient with nonvalvular atrial fibrillation on an anticoagulant after conducting a clinical review of the patient’s care.

The median change from baseline at week 24 in the 6-minute walk distance was 34.4 m in the sotatercept group and 1 m in the placebo group among patients with pulmonary arterial hypertension.

This type of stretching allows for faster tissue oxygenation after the workout and protects from exercise stress.

In a phase 3 trial, the risk of disease progression, relapse, or death was reduced by 27% with polatuzumab vedotin-piiq plus R-CHP compared with R-CHOP in adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

Omidubicel-onlv therapy aims to quicken the recovery of neutrophils and reduce the risk of infection in patients with cancer.

According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.

Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.

Factors (comorbidities, social factors) can largely affect the success of therapies in daily practice, despite findings observed in clinical trials.

And whatever specialty the student or resident decides on, it does not have to define the rest of their career.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

The Hematology/Oncology Pharmacy Association (HOPA) created committees, inclusion statements, and diversity, equity, and inclusion (DEI) checkpoints to improve healthcare for underserved or historically less included populations.

President (2022 to 2023) of the Hematology Oncology Pharmacists Association (HOPA) highlights the many ways that hematology/oncology pharmacists can collaborate with care teams to improve access to care at HOPA Annual Conference 2023 in Phoenix, Arizona from March 29 to April 1.

Follow Pharmacy Times®’ live coverage of the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference in Phoenix, Arizona from March 29 to April 1, 2023.

Axicabtagene ciloleucel demonstrated a 2.5-fold increase in individuals with relapsed/refractory large B-cell lymphoma who were alive at 2 years and did not experience either cancer progression or require the need for additional cancer treatment.